KPT-330
Showing 1 - 25 of 198
Recurrent Melanoma Trial in Columbus (selinexor, Correlative studies)
Active, not recruiting
- Recurrent Melanoma
- selinexor
- Correlative studies
-
Columbus, OhioArthur G. James Cancer Hospital and Solove Research Institute at
Sep 5, 2022
Recurrent Histiocytic and Dendritic Cell Tumor, Recurrent Non-Hodgkin Lymphoma, Refractory Histiocytic and Dendritic Cell Tumor
Recruiting
- Recurrent Histiocytic and Dendritic Cell Neoplasm
- +3 more
- Choline Salicylate
- Selinexor
-
Rochester, MinnesotaMayo Clinic in Rochester
Dec 5, 2022
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage IV Pancreatic Cancer Trial in
Suspended
- Acinar Cell Adenocarcinoma of the Pancreas
- +2 more
- gemcitabine hydrochloride
- +4 more
-
Detroit, Michigan
- +1 more
Feb 2, 2022
MDS Trial in New York (selinexor (KPT-330))
Completed
- Myelodysplastic Syndromes
- selinexor (KPT-330)
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Feb 11, 2022
Advanced Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma Trial in Sacramento
Recruiting
- Advanced Urothelial Carcinoma
- +3 more
- Pembrolizumab
- Selinexor
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Jun 28, 2022
MGMT-Methylated Glioblastoma, Recurrent Glioblastoma, IDH-Wildtype Trial (Selinexor, Temozolomide)
Not yet recruiting
- MGMT-Methylated Glioblastoma
- Recurrent Glioblastoma, IDH-Wildtype
- (no location specified)
Jun 28, 2022
Advanced Alveolar Soft Part Sarcoma, Advanced Soft Tissue Sarcoma, Metastatic Alveolar Soft Part Sarcoma Trial run by the NCI
Recruiting
- Advanced Alveolar Soft Part Sarcoma
- +3 more
- Atezolizumab
- +5 more
-
Bethesda, Maryland
- +1 more
Jan 28, 2023
Multiple Myeloma Trial in Washington, Hackensack (Selinexor 60 MG, Selinexor 80 MG, Selinexor 100 MG)
Recruiting
- Multiple Myeloma
- Selinexor 60 MG
- +6 more
-
Washington, District of Columbia
- +1 more
Feb 3, 2022
Gliosarcoma, Newly Diagnosed, Glioblastoma Trial run by the National Cancer Institute (NCI) (Selinexor, Temozolomide, Generic
Recruiting
- Gliosarcoma
- +2 more
- Selinexor
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Apr 7, 2022
Prolymphocytic Leukemia, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma Trial in Columbus, Salt
Active, not recruiting
- Prolymphocytic Leukemia
- +4 more
- Selinexor
- +3 more
-
Columbus, Ohio
- +1 more
Apr 29, 2022
Leukemia, Acute Myeloid Leukemia, AML Trial in Tampa (Selinexor, Daunorubicin, Cytarabine)
Completed
- Leukemia
- +2 more
- Selinexor
- +2 more
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Sep 30, 2022
Myelofibrosis, Moderate Thrombocytopenia Trial (Selinexor)
Not yet recruiting
- Myelofibrosis
- Moderate Thrombocytopenia
- (no location specified)
Jul 31, 2023
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Rochester (Carfilzomib, Dexamethasone, Pomalidomide)
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Carfilzomib
- +5 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jun 3, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in United States (drug, biological, other)
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Carfilzomib
- +4 more
-
Des Moines, Iowa
- +8 more
Jan 12, 2023
Multiple Myeloma, Myeloma-Associated Amyloidosis Trial in Saint Louis (Selinexor, Lenalidomide, Dexamethasone)
Not yet recruiting
- Multiple Myeloma
- Myeloma-Associated Amyloidosis
- Selinexor
- +2 more
-
Saint Louis, MissouriWashington University School of Medicine
Apr 6, 2023
Rhabdoid Tumor, Atypical Teratoid/Rhabdoid Tumor, Atypical Teratoid/Rhabdoid Tumor of CNS Trial in Memphis (Idasanutlin,
Not yet recruiting
- Rhabdoid Tumor
- +3 more
-
Memphis, TennesseeSt. Jude Children's Research Hospital
Jul 11, 2023
Relapsed or Refractory Acute Myeloid Leukemia Trial in Taiyuan (Selinexor, Homoharringtonine, Daunorubicin)
Recruiting
- Relapsed or Refractory Acute Myeloid Leukemia
- Selinexor
- +5 more
-
Taiyuan, Shanxi, ChinaTao Wang
Feb 9, 2023
Solid Tumor Malignancy Trial in Hackensack (Selinexor, Irinotecan)
Withdrawn
- Solid Tumor Malignancy
-
Hackensack, New JerseyJohn Theurer Cancer Center at HackensackUMC
Dec 14, 2021
DLBCL, Not Otherwise Specified Trial in Chongqing (selinexor)
Recruiting
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
-
Chongqing, Chongqing, ChinaChongqing University Cancer Hospital
Mar 27, 2023
Multiple Myeloma Trial in Tampa (Selinexor, Melphalan, Dexamethasone)
Completed
- Multiple Myeloma
- Selinexor
- +4 more
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Nov 2, 2022
Metastatic Colorectal Cancer Trial in Los Angeles, Newark, Plantation (Selinexor, Pembrolizumab, Trifluridine)
Terminated
- Metastatic Colorectal Cancer
- Selinexor
- +3 more
-
Los Angeles, California
- +2 more
Jan 24, 2023